Arthur J. Gallagher & Co. heads into the week down 1.4% with short interest rising at its fastest weekly pace in months — while the Street still firmly backs the stock.
Short interest has climbed to 3.1% of the free float, up 6.5% on the week and adding roughly 160,000 shares. That's the sharpest weekly build in the 30-day window, reversing a modest decline through August. The lending market remains relaxed — availability is running at 783%, meaning there are nearly eight shares available to borrow for every one currently lent out, well within the normal range. Cost to borrow ticked up 5% on the week but is still only 0.49%, firmly in "easy borrow" territory. The ORTEX short score sits at 42.2, mid-range and drifting only marginally higher. None of this points to a conviction bear case — the build looks tentative rather than aggressive.
Options positioning is equally muted. The put/call ratio came in at 0.49 on Monday, fractionally above its 20-day average of 0.47 and less than 0.4 standard deviations from the mean. The 52-week range for the PCR spans 0.33 to 0.91, which puts the current reading comfortably in the middle of the pack. There is no hedging surge, no call-side enthusiasm — just routine positioning in a stock that has drifted 1.3% lower over the week.
The analyst community remains overwhelmingly bullish, even as it starts to fine-tune targets. This morning, Mizuho lowered its price target on AJG to $292 from $300, while holding its Outperform rating — a mild trim, not a retreat. That follows a cluster of target raises in late July and early August from Morgan Stanley ($290, raised from $270), Argus ($300, from $267), Citigroup ($285, from $250), and UBS ($299). The mean analyst target is $292, roughly 18% above the current price of $248. The bull case rests on strong organic growth in the brokerage and risk management segments, continued M&A optionality, and forward earnings revisions that rank in the 98th percentile universe-wide. Bears point to AssuredPartners acquisition margin dilution and softening commercial pricing — but with every firm that raised targets post-Q2 still holding Buy or Outperform, the dissent is thin. RBC's target of $310 is the high-water mark on the Street.
The stock's Q2 results told a less comfortable story. AJG fell 7.2% the day after its July 30 print and extended that to a 6.4% five-day loss — the kind of reaction that leaves bulls nursing paper losses even as targets stay elevated. The next earnings event is October 29. With the stock now 18% below consensus targets and trading at a trailing P/E of 17.6x and EV/EBITDA of 13.1x, the valuation has de-rated somewhat from Q2 highs. The factor score on EV/EBIT ranks in just the 10th percentile, suggesting the market is not yet pricing in a recovery. The forward earnings revision score at the 98th percentile is the strongest counterpoint — analysts see earnings improving sharply, even if the market hasn't yet given credit for it.
Peer performance adds context to the week's softness. BRO fell 1.4% on the week, closely tracking AJG. AON dropped 3.5% and RYAN fell 4.1%, suggesting sector-wide pressure rather than a stock-specific issue. GSHD lost 4.8%. Only PLMR and KNSL bucked the trend, each posting gains. Institutional ownership gives little cause for alarm — BlackRock, Vanguard, Capital Research, and Fidelity together hold roughly 28% of shares, and recent filings show mostly stable or modestly increasing positions. The one notable shift is JPMorgan's 13G/A filed in July, which showed its stake declining from 7.8% to 5.5% of shares — a reduction worth watching given the scale.
The insider picture is less clean. Over the past 90 days, net open-market activity shows 27,500 shares sold on balance, worth roughly $7.3 million. The most notable discrete transaction was VP Scott Hudson's exercise-and-sell on September 2, with a $3.2 million sale at $264. General Counsel Walter Bay sold 12,000 shares at $270 on August 24 for a further $3.2 million. Neither trade was under a 10b5-1 plan, which gives them more signal value than routine programmatic selling — though both are VPs, not C-suite. The CEO-level action on September 8 was a gift transfer, not a market sale, and carries no directional weight.
October 29 brings the next earnings test, and with the stock still digesting a 7% post-Q2 drop, the gap between analyst targets and market price makes that print the next defining moment for AJG.
See the live data behind this article on ORTEX.
Open AJG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
